Dimensional Fund Advisors LP Buys 31,454 Shares of Lantheus Holdings, Inc. $LNTH

Key Points

• Dimensional Fund Advisors LP increased its stake in Lantheus Holdings by 2.3%, owning approximately 2.01% of the company, which is valued at $134.5 million.
• Insiders, including Farallon Partners and Rajiv A. Patel, sold a combined total of 6,838,066 shares worth nearly $384.4 million in the last 90 days, representing a 49.18% decrease in their positions.
• Analysts have lowered Lantheus's price targets, with JMP Securities cutting its target from $112 to $73, although the consensus rating remains a "Moderate Buy" with a target price of $105.50.

Dimensional Fund Advisors LP increased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,378,536 shares of the medical equipment provider's stock after purchasing an additional 31,454 shares during the period. Dimensional Fund Advisors LP owned approximately 2.01% of Lantheus worth $134,534,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of LNTH. Janus Henderson Group PLC raised its position in Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after buying an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC raised its position in Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after buying an additional 2,361,000 shares during the last quarter. Westfield Capital Management Co. LP raised its position in Lantheus by 2.2% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider's stock valued at $155,101,000 after buying an additional 34,052 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after buying an additional 435,445 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC raised its position in Lantheus by 39.1% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock valued at $87,124,000 after buying an additional 273,838 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,838,066 shares of company stock valued at $384,430,031. 2.00% of the stock is owned by insiders.

Lantheus Stock Performance

LNTH traded up $0.54 during trading hours on Wednesday, hitting $56.20. The stock had a trading volume of 88,225 shares, compared to its average volume of 1,202,938. The company's fifty day simple moving average is $70.60 and its 200 day simple moving average is $83.77. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The stock has a market cap of $3.82 billion, a PE ratio of 14.94 and a beta of 0.14. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $378.05 million during the quarter, compared to analysts' expectations of $389.69 million. During the same period last year, the business posted $1.80 EPS. The company's revenue was down 4.1% compared to the same quarter last year. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on LNTH shares. B. Riley lowered their price target on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Mizuho decreased their target price on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. Finally, JMP Securities decreased their target price on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research report on Thursday, August 7th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Lantheus has an average rating of "Moderate Buy" and a consensus target price of $105.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.